Drugmakers are lobbying Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the ...

India, China, and the European Union, which produce the vast majority of active pharmaceutical ingredients (APIs) used in ...

With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...

Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as ...

Pfizer in 2019 sold $20 billion of drugs in the U.S. Its federal tax bill? Zero. That revelation was part of a Senate Finance ...

Two European-headquartered drugmakers told Reuters this week they are sending as much of their medicines across the Atlantic ...

AscellaHealth has introduced its latest Specialty & Rare Pipeline Digest™, a quarterly publication designed to provide ...

Tariffs are one way for Donald Trump to achieve tax cuts, and Irish-based pharma industry may be a golden goose ready for ...

President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...

In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.

Drugmakers are pushing back against pharmaceutical tariffs. Some companies are lobbying the Trump administration to phase in ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...